A5031049647- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Lipoproteins and Cardiovascular Health
- Atherosclerosis and Cardiovascular Diseases
- Systemic Lupus Erythematosus Research
- Genomic variations and chromosomal abnormalities
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Breast Cancer Treatment Studies
- Advanced Biosensing Techniques and Applications
- Bacteriophages and microbial interactions
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Prenatal Screening and Diagnostics
- Photoacoustic and Ultrasonic Imaging
- Congenital limb and hand anomalies
- Monoclonal and Polyclonal Antibodies Research
- Chromosomal and Genetic Variations
The University of Texas MD Anderson Cancer Center
2023-2025
The University of Texas Health Science Center at Houston
2023
University of New Mexico
2023
Checkpoint immunotherapy has yielded meaningful responses across many cancers but shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3's role cancer progression, predictive biomarkers for B7-H3-targeted therapy, combinatorial strategies. Our multi-omics analyses identified B7-H3 one of the most abundant checkpoints tumors...
Elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Inhibitors proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator LDL-C metabolism, have emerged as promising approaches for reducing elevated levels. Here, we evaluated cholesterol-lowering efficacy virus-like particle (VLP) based vaccines that target epitopes found within LDL receptor (LDL-R) binding domain PCSK9. In...
Abstract Despite receiving surgical or medical castration, most prostate cancer (PCa) patients eventually progress to castration-resistant (CRPC), where the androgen receptor (AR) continues drive disease progression. Genomic studies have identified a unique subtype of PCa marked by mutations in speckle-type BTB/POZ protein (SPOP), which lead stabilization AR and its co-activators been associated with prolonged responses deprivation therapies favorable prognoses. However, SPOP frequently...
Abstract Elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor in the development of atherosclerotic cardiovascular disease (ASCVD). Inhibitors proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator LDL-C metabolism, have emerged as promising approaches for reducing elevated levels. Here, we evaluated lowering efficacy virus-like particle (VLP) based vaccines that target epitopes found within LDL receptor (LDL-R) binding domain PCSK9. In both...